Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04144738 · ClinicalTrials.gov registry record
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"
A clinical trial, sponsored by Exact Sciences Corporation.
- Completed
- Registry status
- 26,758
- Enrollment target
NCT04144738: Completed study, sponsored by Exact Sciences Corporation.
NCT04144738 is a clinical trial that has completed, run by Exact Sciences Corporation. The registered enrollment target is 26,758 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04144738 has completed, sponsored by Exact Sciences Corporation.
- COMPLETED
- Registry status
- 26,758 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the sensitivity for colorectal cancer (CRC) and specificity of the mt-sDNA 2.0 test.
Interventions
- PROCEDURE Colonoscopy
- DIAGNOSTIC_TEST mt-sDNA 2.0 screening test
- DIAGNOSTIC_TEST FIT test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26,758 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2023-03-30 |
What the finished NCT04144738 record still lists
NCT04144738 is an observational study that tracks outcomes without assigning an intervention. Its 26,758 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which Colonoscopy is the first listed.
NCT04144738 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04144738 about?
NCT04144738 is a clinical study titled "Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"". The primary objective of this study is to assess the sensitivity for colorectal cancer (CRC) and specificity of the mt-sDNA 2.0 test.
What is the current status of trial NCT04144738?
This trial is currently completed. The enrollment target is 26,758 participants. The study started on 2019-11-15. Estimated completion is 2023-03-30.
What interventions are being tested in trial NCT04144738?
The interventions under investigation include: Colonoscopy (PROCEDURE), mt-sDNA 2.0 screening test (DIAGNOSTIC_TEST), FIT test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04144738?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04678193 · 27,000 participants
COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy
- NCT04494945 · 27,500 participants · NA
Identifying and Caring for Individuals With Inherited Cancer Syndrome
- NCT07300839 · 25,500 participants · Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
- NCT03175302 · 25,240 participants
PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI